{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:46:47Z","timestamp":1773722807311,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Emer Care"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Novel oral anticoagulants offer equivalent or improved therapeutic profiles compared with warfarin, with less risk of bleeding, no interactions with food, and no need for routine laboratory monitoring. Caution must be exercised in using these drugs in certain patient populations, for example, renal insufficiency, those receiving additional antithrombotic therapy, those with questionable compliance, children, and those with a high risk of gastrointestinal bleeding. One of the novel oral anticoagulants, rivaroxaban, is a direct Factor Xa inhibitor, used to reduce risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism. We report a child who presented abnormal coagulation tests after unintended ingestion of 4 tablets of rivaroxaban. The patient was treated with fresh frozen plasma as well as admitted to intensive care and improved several hours later. We discuss his presentation and review of the literature on this topic.<\/jats:p>","DOI":"10.1097\/pec.0000000000001392","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T18:04:38Z","timestamp":1516125878000},"page":"e44-e46","source":"Crossref","is-referenced-by-count":7,"title":["Accidental Rivaroxaban Intoxication in a Boy"],"prefix":"10.1097","volume":"35","author":[{"given":"Julieta","family":"Weirthein","sequence":"first","affiliation":[{"name":"Division of Emergency Medicine, Sourasky Medical Center, Tel Aviv, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Scolnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nili Yanai","family":"Milshtein","sequence":"additional","affiliation":[{"name":"Division of Pediatric Emergency Medicine, Department of Pediatrics, Dana's Children Hospital, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Capua","sequence":"additional","affiliation":[{"name":"Division of Pediatric Emergency Medicine, Department of Pediatrics, Dana's Children Hospital, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Glatstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230930","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1538-7836.2003.00021.x","article-title":"Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies","volume":"1","year":"2003","journal-title":"J Thromb Haemost"},{"key":"bib2-20230930","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MCC.0b013e3283269e4d","article-title":"Correction of coagulopathy in warfarin associated cerebral hemorrhage","volume":"15","year":"2009","journal-title":"Curr Opin Crit Care"},{"key":"bib3-20230930","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-5223(19)38448-X","article-title":"Toward a better understanding of the hemodynamic effects of protamine and heparin interaction","volume":"87","year":"1984","journal-title":"J Thorac Cardiovasc Surg"},{"key":"bib4-20230930","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrcardio.2012.19","article-title":"Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation","volume":"9","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"bib5-20230930","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","year":"2015","journal-title":"Atherosclerosis"},{"key":"bib6-20230930","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","year":"2012","journal-title":"Thromb Res"},{"key":"bib7-20230930","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/acem.12865","article-title":"Comparison of four bleeding risk scores to identify rivaroxaban-treated patients with venous thromboembolism at low risk for major bleeding","volume":"23","year":"2016","journal-title":"Acad Emerg Med"},{"key":"bib8-20230930","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct Factor Xa inhibitor","volume":"3","year":"2005","journal-title":"J Thromb Haemost"},{"key":"bib9-20230930","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"bib10-20230930","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/CIRCULATIONAHA.111.030148","article-title":"The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"bib11-20230930","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3810\/hp.2014.10.1144","article-title":"Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers","volume":"42","year":"2014","journal-title":"Hosp Pract (1995)"},{"key":"bib12-20230930","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","year":"2015","journal-title":"Circulation"},{"key":"bib13-20230930","first-page":"57","article-title":"Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants","volume":"8","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"key":"bib14-20230930","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","year":"2011","journal-title":"Stroke"},{"key":"bib15-20230930","first-page":"1568","article-title":"Clinical applications of 4-factor prothrombin complex concentrate: a practical pathologist's perspective","volume":"139","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"bib16-20230930","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cll.2014.06.007","article-title":"Treatment of intracerebral hemorrhage associated with new oral anticoagulant use: the neurologist's view","volume":"34","year":"2014","journal-title":"Clin Lab Med"}],"container-title":["Pediatric Emergency Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006565-201903000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:19:44Z","timestamp":1696061984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006565-201903000-00018"}},"subtitle":["Some Lessons in Managing New Oral Anticoagulants in Children"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pec.0000000000001392","relation":{},"ISSN":["1535-1815","0749-5161"],"issn-type":[{"value":"1535-1815","type":"electronic"},{"value":"0749-5161","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}